
## Biosimilars: A Safe & Effective Option for Patients

In the U.S., the U.S. Food and Drug Administration (FDA) is approving more biosimilars and patients are benefitting from these new medicines. Broader access to these safe, effective treatments allow patients to initiate biologic therapy earlier in their treatment programs.<sup>1</sup>

A biosimilar is a biologic medicine that is

## **HIGHLY**


to a brand biologic medicine.



More than 30 BIOSIMILARS have now been approved by the FDA. Biosimilars have the potential to increase patient access to lower-cost treatment and reduce the price of brand-name biologics.



Same safety and efficacy as their biologic counterpart



Same mechanism of action



Rigorous FDA testing and review; lower cost to patients and the health system



Companies that manufacture biosimilars are committed to providing safe, effective products

Biosimilars are: Safe, effective, more affordable and offer improved patient access.









1. Janjigian YY, et al. Talking to patients about biosimilars. Future Oncol. 2018;14(23):2403-2414.



Document adapted from materials provided by the Biosimilars Council. Fresenius Kabi is a member of the Biosimilars Council, a division of AAM.

